Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications
Authors
Keywords
-
Journal
Journal of Crohns & Colitis
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2020-06-30
DOI
10.1093/ecco-jcc/jjaa050
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-based Data
- (2019) Stephanie Coward et al. GASTROENTEROLOGY
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
- (2019) Nicholas A Kennedy et al. Lancet Gastroenterology & Hepatology
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases
- (2018) Julien Kirchgesner et al. GASTROENTEROLOGY
- Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD
- (2018) Sara Lega et al. INFLAMMATORY BOWEL DISEASES
- Upfront Combination Therapy, Compared with Monotherapy, for Patients Not Previously Treated with a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study
- (2018) Laura E. Targownik et al. Clinical Gastroenterology and Hepatology
- No Increase in Immunomodulator Use in Combination with Anti-TNF Therapy in the Post Sonic ERA
- (2017) Evan Elias et al. GASTROENTEROLOGY
- Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
- (2017) Magali Lemaitre et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
- (2017) Jean-Frederic Colombel et al. LANCET
- Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014
- (2016) J. Kirchgesner et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Monotherapy and a Combination with Azathioprine for Crohn’s Disease: A Prospective, Randomized Trial
- (2016) Takayuki Matsumoto et al. Journal of Crohns & Colitis
- Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission
- (2016) Aurélien Amiot et al. Clinics and Research in Hepatology and Gastroenterology
- Development and Validation of an Administrative Case Definition for Inflammatory Bowel Diseases
- (2016) Ali Rezaie et al. CANADIAN JOURNAL OF GASTROENTEROLOGY
- Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States
- (2015) Ashwin N. Ananthakrishnan et al. Clinical Gastroenterology and Hepatology
- Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti–Tumor Necrosis Factor Therapy for Crohn’s Disease: A Meta-analysis of Placebo-controlled Trials
- (2015) Jennifer L. Jones et al. Clinical Gastroenterology and Hepatology
- Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease
- (2015) R. J. Colman et al. Journal of Crohns & Colitis
- Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
- (2014) Y. Mazor et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study
- (2013) Nabeel Khan et al. GASTROENTEROLOGY
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model
- (2011) Corey A. Siegel et al. Clinical Gastroenterology and Hepatology
- A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
- (2010) David S. Kotlyar et al. Clinical Gastroenterology and Hepatology
- Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy
- (2010) H. Sokol et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started